• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Apellis Pharmaceuticals Inc (NQ: APLS )

    27.55 +0.29 (+1.06%)
    Streaming Delayed Price Updated: 2:15 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Apellis Pharmaceuticals Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
    It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. 
    Via The Motley Fool
    Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
    Via Benzinga
    Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
    Via Benzinga
    Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
    Via Benzinga
    Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
    Via Benzinga
    Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
    William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
    Via Benzinga
    Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    What Analysts Are Saying About Apellis Pharmaceuticals Stock
    Via Benzinga
    Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
    Via Benzinga
    Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    What's Going With Apellis Pharmaceuticals Stock Friday?
    Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following... 
    Via Benzinga
    Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
    The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst. 
    Via Investor's Business Daily
    Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
    New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some. 
    Via InvestorPlace
    Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
    Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary... 
    Via Benzinga
    Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.